“I have Alzheimer's and we'll talk about the biomarkers I'd like to see your mom get. But there's things now that give people hope. Like I don't just have to go on an anti-amyloid antibody like Lecanemab, Donanemab, which they just showed in a Cochrane review is really not making much difference. Now, maybe if you address the infections like Lyme”
“Donanemab, Kisunla. All these three drugs reduce and eventually eliminate brain levels of tau so that when you, the person's been on the medication for some time, there's no longer any plaque in the brain.”
“We titrate patients up very slowly. And in fact, recently for the drug Donanemab, which is a third drug in this group, they have the FDA has approved a slightly slower titration protocol than initially used because they too have noticed that a slower protocol is helpful in drastically reducing risk of side effects.”
“This is a very small change. And in fact, in the early data on Donanemab, there was really no change on the CDR sum of box scores between patients on drug versus patients not on drug. But I do believe that many of these patients had moderate to severe disease.”
“I have a pair of identical twins, and I take care of one of the two. And the one, she just, you know, she was on a monoclonal antibody, initially on Aducanumab, and then on Donanemab. And she did much better than her identical twin, who was in a facility. And my patient actually also had heart disease.”